Free Trial
NASDAQ:HYPD

Hyperion DeFi Q1 2025 Earnings Report

Hyperion DeFi logo
$5.50 +0.05 (+0.92%)
As of 08/7/2025 04:00 PM Eastern

Hyperion DeFi EPS Results

Actual EPS
-$1.59
Consensus EPS
-$7.20
Beat/Miss
Beat by +$5.61
One Year Ago EPS
N/A

Hyperion DeFi Revenue Results

Actual Revenue
$1.60 million
Expected Revenue
$1.60 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Hyperion DeFi Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Sunday, May 18, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Hyperion DeFi's next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Hyperion DeFi Earnings Headlines

Hyperion DeFi (HYPD) versus The Competition Critical Analysis
Hyperion DeFi (HYPD) & The Competition Critical Review
Protect Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Hyperion DeFi (HYPD) vs. Its Rivals Head to Head Review
Reviewing Hyperion DeFi (HYPD) & Its Competitors
See More Hyperion DeFi Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hyperion DeFi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hyperion DeFi and other key companies, straight to your email.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

View Hyperion DeFi Profile

More Earnings Resources from MarketBeat